Skip to content

Amino Acids in the Blood After Eating Yoghurt and Milk Proteins

Determination of the early postprandial essential amino acid bioavailability of yogurt vs milk. A randomized controlled clinical trial in healthy volunteers. - A bioavailability study - - Amino acids in the blood after consumption of yogurt and milk proteins

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58124
Enrollment
30
Registered
2025-09-02
Start date
2025-11-10
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amino acids, Yogurt, Milk Building blocks of protein, Yogurt, Milk

Interventions

Full fat yogurt (fermented)generic full fat pasteurized milk (non-fermented)

Sponsors

Danone Global research & Innovation center
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Age = 18 and = 40 years at the time of ICF signature Body Mass Index (BMI) = 18.5 and = 29.9 kg/m2 Signed informed consentWillingness and ability to comply with the protocol Judged by the Investigator to be in good health

Exclusion criteria

Exclusion criteria:  Any known surgery or ongoing medical condition that interferes significantly with protein absorption and digestion, and/or gastrointestinal (GI) function in the opinion of the investigator, including but not limited to the following: phenylketonuria, pancreatitis, short bowel syndrome, inflammatory bowel disease, celiac disease, gastroesophageal reflux disease, gastric ulcer, chronic gastritis, gastrointestinal cancer, oesophageal and/or gastric surgery, and any cardiovascular disease (such as hypertension, arrhythmia, or atrial fibrillation) which is not controlled with the use of medication/therapy.  Known renal or hepatic diseases that may interfere with protein metabolism in the opinion of the investigator, including but not limited to acute hepatitis, chronic liver disease, nephritis, cystinuria, chronic kidney disease.Use of systemic medication within the past 3 weeks prior to screening which in the opinion of the investigator may influence gastric acid production and/or gastrointestinal motility or function and/or protein metabolism (e.g., antibiotics, anticonvulsants, prokinetics, antacids or gastric acid inhibitors, opioid analgesics, anticoagulants, corticosteroids, laxatives, growth hormone, testosterone, immunosuppressants, or insulin).  Known Diabetes Mellitus Type I or Type II, insulin resistance, or metabolic syndrome.Any ongoing cancer and/or cancer treatment (except for non-melanoma skin cancer or carcinoma in situ).Known anaemia. A blood donation within 56 days (8 weeks) for men; or 122 days (4 months) for women; prior to the screening.Any known bleeding disorder.Adherence to a strict dietary regime (e.g. vegetarian/ vegan/ paleo/ ketogenic/ intermittent fasting/ high protein diet (>1.6 g/kg body weight/day)) or a weight loss program.Any known allergies or intolerances to ingredients of the study product, i.e. cow’s milk allergies, lactose intolerance.Known pregnancy and/or lactation.Current smoking / vaping / use of e-cigarette / or stopped smoking for < 1 month prior to screening (except for incidental smoking of = 3 cigarettes/ e-cigarettes/ cigars/ pipes per week on average in the last month prior to screening).Average alcohol use of > 21 glasses per week for men or > 14 glasses per week for women (on average during the last 6 months prior to screening). Drug or medicine abuse in the opinion of the investigator. Current eating disorders, e.g. anorexia nervosa, bulimia nervosa, binge eating disorder.Use of protein, amino acid, or creatine supplements within 4 weeks prior to screening.Known difficulties with placement of and/or blood drawings from a cannula. Participation in any other clinical study with investigational or marketed products concomitantly or within four weeks before study visit 1. Major medical or surgical event requiring hospitalization within the preceding 3 months and/or scheduled in the period of study participation relevant in the opinion of the investigator. Investigator’s uncertainty about the willingness or ability of the participant to comply with the protocol requirements.Employees of DGRIC and of the investigational site and/or their family members or relatives.

Design outcomes

Primary

MeasureTime frame
The primary outcome parameter in this study is iAUC0-120  for Essential Amino Acids (EAA) calculated from postprandial blood amino acid concentrations. 

Secondary

MeasureTime frame
Secondary outcome parameters in this study are EAA iAUC0-300, TAA iAUC0-120, TAA iAUC0-300, EAA Cmax, TAA Cmax calculated from postprandial blood amino acid concentrations. 

Countries

Netherlands

Contacts

Public ContactB.C.E.M. Wolfs

Danone Global research & Innovation center

brigitte.wolfs@external.danone.com0031621374373

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026